RDNT
RadNet, Inc.
Diagnostics & Research · Healthcare · United States
73.65
close · 2026-10-29
value
29
cheaper than peers29
quality
41
stronger fundamentals41
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| price to sales | 2.83× | 66 |
| price to book | 5.28× | 53 |
| EV to EBITDA | 29.43× | 26 |
| forward P/E | 89.82× | 3 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 22.1% | 76 |
| return on equity | 1.8% | 50 |
| operating margin | -2.8% | 48 |
| debt to equity | 143.0% | 16 |
4 of 4 measures available
Facts
| market cap | $6B |
| free cash flow | $190.5M |
| employees | 11,000 |
| first trade | 1997-01-03 |
| next earnings | 2026-11-08 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.25 | 0.04 | 0.05 | 0.17 |
| free cash flow | $85.6M | $45.0M | $44.3M | $27.0M |
| net income | -$18.7M | $2.8M | $3.0M | $10.7M |
| revenue | $2.04B | $1.83B | $1.62B | $1.43B |
| unusual items | -$28.5M | -$26.0M | -$19.3M | $35.4M |